TrivarX Bilan de santé

Santé financière contrôle des critères 3/6

TrivarX possède un total de capitaux propres de A$9.9M et une dette totale de A$0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont A$11.1M et de A$1.2M.

Informations clés

Ratio d'endettement

AU$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	AU$848.10k
Fonds propres	AU$9.89m
Total du passif	AU$1.17m
Total des actifs	AU$11.07m

Mises à jour récentes de la santé financière

Pas de mise à jour

Recent updates

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de TRI ( A$915.2K ) ne couvrent pas ses passifs à court terme ( A$1.2M ).

Passif à long terme: TRI n'a pas de passif à long terme.

Historique et analyse du ratio d'endettement

Niveau d'endettement: TRI est sans dette.

Réduire la dette: TRI n'a aucune dette par rapport à il y a 5 ans, lorsque son ratio d'endettement était 32%.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: TRI dispose de moins d'un an de piste de trésorerie sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: TRI dispose de moins d'un an de marge de trésorerie si le flux de trésorerie disponible continue de croître à un taux historique de 22.5 % chaque année.

TrivarX Bilan de santé

Santé financière contrôle des critères 3/6

Informations clés

Mises à jour récentes de la santé financière

Recent updates

TrivarX Limited, Annual General Meeting, Nov 28, 2024

TrivarX Limited Appoints John H. Mathias II as Non-Executive Director, Effective 1 October 2024

New major risk - Financial position

Less than half of directors are independent

TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.

Less than half of directors are independent

Medibio Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.006 loss in FY 2022)

Medibio Limited, Annual General Meeting, Oct 06, 2023

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.006 loss in FY 2022)

Less than half of directors are independent

First half 2023 earnings released

Medibio Limited Appoints Christopher Ntoumenopoulos as Director

Less than half of directors are independent

Medibio Limited Announces Resignation of Stephen Mitchley as a Director

Medibio Limited Appoints David Trimboli as the Company's New Non-Executive Chair

Full year 2022 earnings released: AU$0.006 loss per share (vs AU$0.001 loss in FY 2021)

Medibio Limited, Annual General Meeting, Nov 11, 2022

Medibio Limited Appoints Thomas R. Young as CEO

Full year 2022 earnings released: AU$0.006 loss per share (vs AU$0.001 loss in FY 2021)

Medibio Appoints David Trimboli to Its Board of Directors as Non-Executive Director

Medibio Limited Announces Sleep Analysis Depressive Burden Study Clinical Trial Commencement

Medibio Limited Announces Resignation of Claude Solitario as Managing Director

Medibio Limited Announces Executive Changes

Medibio Limited Announces That A DSM-V1 Diagnosis Will Be Included as Primary Comparator for the Purposes of Assessing the Efficacy of Its Depression Algorithms, MEB-001

Less than half of directors are independent

Medibio Limited Appoints Matt Mesnik as Non-Executive Director

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Medibio Limited Appoints Stephen Mitchley as Non-Executive Director

Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.004 loss in FY 2020)

Medibio Limited to Resubmit FDA 510(K) Application for its Sleep Staging Software, MEBbsleep

First half 2021 earnings released: AU$0.001 loss per share (vs AU$0.003 loss in 1H 2020)

Medibio Limited, Annual General Meeting, Mar 24, 2021

Medibio Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.

Medibio Limited Receives CE Mark Approval for Its Sleep Staging Software, MEBsleep

Medibio Limited Commences the Initial Phase of Testing of its Consumer Mental Health App

Medibio Limited Announces US FDA Advises Further Data Needed for Mebsleep Approval

Medibio Limited Signs Global Master License & Services Agreement with Compass Group Plc

Medibio Limited Signs Clinical Trial Agreement with MedBridge Healthcare

Medibio Limited Submits Request for FDA Breakthrough Device Designation

Full year earnings released - AU$0.0044 loss per share

Full year earnings released - AU$0.0044 loss per share

Medibio Limited has completed a Follow-on Equity Offering in the amount of AUD 1.517195 million.

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines